Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Buprenorphine

USE IF: OUD induction/maintenance, chronic pain, selected acute pain, opioid option in CKD

AVOID IF: Inadequate withdrawal before induction, severe respiratory compromise, unsafe benzodiazepine co-use

Buprenorphine

Partial mu-opioid receptor agonist / kappa-antagonist

OUDPartial agonistHigh-affinity opioidMATTransdermalPrecipitated withdrawal

Indication

OUD induction/maintenance, chronic pain, selected acute pain, opioid option in CKD

At a glance

INDICATION -> OUD treatment and selected chronic pain with safer respiratory profile than full agonists

ADULT DOSE -> OUD induction 2–4 mg SL, titrate to 8–16 mg day 1–2

MAX DOSE -> No absolute OUD ceiling; >24 mg/day may be appropriate in selected patients

CONTRA -> Starting before COWS >=8, severe respiratory compromise, unsafe benzodiazepine co-use

ANTIDOTE -> Naloxone needs high-dose bolus + infusion; reversal often incomplete due to high receptor affinity

Quick facts

Onset

15–45 min (SL/buccal); ~15 min (IM); immediate (IV)

Duration

Peak 40 min–3.5 h (SL), 1–2 h (IV); duration 24–72 h (SL), 6–8 h (IV analgesia). Half-life ~24–42 h (SL).

Routes

SL, buccal, IV, IM, SC, transdermal, depot injection, implant

Pregnancy

Preferred MOUD option in many settings; monoproduct often preferred

Renal

Usually no dose adjustment

Hepatic

Reduce in moderate/severe impairment; avoid combo products in severe hepatic disease

Do not miss

Time to action: 15—45 min (SL/buccal), immediate (IV)

Max dose

  • No hard OUD maximum; 16 mg/day is a common target, but >24 mg/day may be clinically appropriate.

Critical risks

  • Precipitated withdrawal.
  • Respiratory depression with benzodiazepines/alcohol.
  • Neonatal opioid withdrawal syndrome (NOWS).

Antidote

  • Naloxone reversal is often incomplete/delayed.
  • Higher bolus dosing plus infusion is commonly required.

High-risk scenarios

  • Fentanyl-era induction.
  • Severe hepatic impairment.
  • Perioperative pain in OUD patients.

Key interactions

  • Benzodiazepines.
  • CYP3A4 inhibitors/inducers.
  • MAOIs.
  • Serotonergic drugs.

Indications

Primary

  • OUD induction
  • Stabilization
  • Maintenance

Secondary

  • Moderate-severe acute pain
  • Chronic pain
  • Perioperative pain continuation in OUD

Other

  • Withdrawal management
  • Palliative pain/dyspnea
  • Selected psychiatric augmentation (off-label)

Dosing

Standard: OUD SL induction 2—4 mg; reassess in 1—2 h

Max daily dose

  • No absolute OUD ceiling; individualized dosing is required.
  • 16 mg/day is common, but >24 mg/day may be appropriate in some patients.

Adult - PO

  • SL OUD induction: 2–4 mg, titrate to ~8 mg day 1; maintenance commonly ~16 mg/day.
  • Buccal pain: 75 mcg q12h initially; titrate.
  • Transdermal pain: 5 mcg/h patch weekly initially.

Adult - IV

  • 0.3 mg IV slow; may repeat once after 30–60 min, then q6–8h.

Pediatric

  • Specialist use only.
  • IV: 1.5–3 mcg/kg q6–8h.
  • SL: ~3 mcg/kg q6–8h (specialist).

Renal adjustment

  • Usually no dose adjustment required.

Hepatic adjustment

  • Moderate impairment: reduce starting dose by ~50%.
  • Severe impairment: reduce by ~50%; prefer monoproduct and avoid buprenorphine/naloxone combo.

Warnings

Clinical warnings

  • Precipitated withdrawal if started too early.
  • Respiratory depression risk rises sharply with benzodiazepines/alcohol/CNS depressants.
  • Naloxone reversal may be incomplete and delayed.
  • QTc prolongation can occur at higher doses.
  • Hepatotoxicity reported (higher risk with injection misuse).
  • Dental injury risk with SL/buccal products.
  • Accidental pediatric exposure can be fatal.
  • Can block/reduce added full-agonist opioid effect.

Adverse effects

  • Common: nausea, constipation, dizziness, sedation, headache.
  • Serious: respiratory depression (especially with co-depressants), precipitated withdrawal, hepatotoxicity.

Contraindications / caution

Do not use

  • Hypersensitivity.
  • Significant respiratory depression without monitoring.
  • Acute/severe bronchial asthma without resuscitation support.
  • Paralytic ileus.
  • MAOI use within 14 days.

Use caution / avoid high doses

  • Severe hepatic impairment.
  • Concurrent benzodiazepines/CNS depressants.
  • Fentanyl-dependent patients during induction.
  • Head injury / raised ICP.
  • Severe COPD / OSA.
  • QTc prolongation risk.

Drug interactions

  • Benzodiazepines -> profound sedation/respiratory depression/death.
  • CYP3A4 inhibitors (azoles, macrolides, ritonavir/atazanavir) -> increased buprenorphine levels.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin) -> withdrawal/loss of efficacy.
  • MAOIs -> unpredictable opioid/serotonergic toxicity.
  • SSRIs/SNRIs/TCAs/triptans/tramadol -> serotonin syndrome risk.
  • Full-agonist opioids -> reduced efficacy due to high receptor affinity/blockade.

Special populations

Pediatrics

Specialist protocols only.

Pregnancy

Continue treatment; do not abruptly stop. Monoproduct is often preferred; plan NOWS care.

Breastfeeding

Generally compatible and often encouraged with monitoring; may reduce NOWS severity.

Elderly

Start lower for analgesia; transdermal options may be useful.

Liver disease

Moderate/severe impairment needs dose reduction; avoid combination products in severe disease.

Renal impairment

Preferred opioid option in CKD; usually no adjustment needed.

Administration

  • SL/buccal: allow full dissolution; do not swallow/chew.
  • IV: administer slowly.
  • Patch: apply weekly.
  • Depot SC: healthcare-provider administration only.
  • Rinse mouth after SL/buccal dose and brush teeth after 1 hour.
  • Do not massage depot injection site.
  • Rotate patch/injection sites.
  • Initiate only when moderate withdrawal is present (e.g., COWS >=8–12) to avoid precipitated withdrawal.

Infusion / dilution

  • IV analgesic dosing only; no routine continuous ICU infusion standard.

Monitoring

  • LFTs at baseline and periodically.
  • Pregnancy test when relevant before combo product use.
  • UDS for OUD monitoring.
  • Respiratory rate and SpO2.
  • COWS before induction and during early titration.
  • Sedation/CNS status.
  • Cravings/withdrawal symptoms.
  • Dental health.
  • QTc when risk factors/high doses are present.
  • Bowel function.

Overdose / toxicity

PRIORITIZE airway and ventilation (naloxone may be incomplete).

Recognition

  • Toxic dose is variable; severe toxicity is more likely with benzodiazepines/alcohol or pediatric exposure.
  • Sedation, miosis, respiratory depression, coma.
  • Patch/depot exposure may prolong toxicity.

Immediate actions

  • Naloxone 2–4 mg IV; repeat/escalate as needed.
  • Continuous naloxone infusion is often required.
  • Remove transdermal patch if present.
  • Ventilatory support is frequently required.

Antidote

  • Naloxone with high-dose bolus plus infusion; reversal often incomplete due to high receptor affinity.

Decontamination

  • Per local toxicology protocol when appropriate.

Escalation

  • ICU/airway management for refractory hypoventilation.
  • Infusion around 4 mg/70 kg/h may be needed in severe cases.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

Precipitated withdrawal

  • Precipitated withdrawal is the key buprenorphine error.

Fentanyl-era induction

  • Micro-induction/low-dose induction can reduce precipitated withdrawal risk in fentanyl-era OUD.

Dose ceiling myth

  • 24 mg/day is not a hard ceiling for OUD.

Naloxone expectations

  • Naloxone 0.4 mg is usually inadequate in buprenorphine overdose.

Acute pain strategy

  • Acute pain on buprenorphine often needs higher-than-usual full-agonist doses.

Perioperative continuity

  • Continue buprenorphine perioperatively in most OUD patients.

CKD advantage

  • One of the best opioid options in CKD.

Formulation caution

  • Formulations are not mg-for-mg interchangeable.

Dental counseling

  • SL/buccal formulations require dental counseling.

Ceiling effect

  • Ceiling effect reduces respiratory depression risk vs full agonists (but not zero risk with co-depressants).

Pharmacokinetics

  • SL/buccal bioavailability varies by formulation.
  • Highly lipophilic and highly protein bound.
  • Hepatic CYP3A4 metabolism to norbuprenorphine.
  • Predominantly biliary/fecal elimination.
  • Long half-life supports once-daily OUD dosing and depot formulations.
  • Not significantly dialyzable.

Mechanism of action

  • High-affinity partial agonist at mu-opioid receptor.
  • Antagonist/inverse agonist at kappa receptor.
  • Slow dissociation leads to prolonged receptor occupancy and opioid blockade.
  • Respiratory depression shows ceiling effect (analgesia does not have a strict ceiling).

Common brand names

Saudi Arabia

Temgesic · Subutex · Butrans

Global

Buprenex · Suboxone · Zubsolv · Sublocade · Brixadi · Buvidal · Belbuca · Transtec

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Most GCC/Middle East access is hospital-restricted and more commonly for analgesia than MOUD.
  • Temgesic is among the most widely recognized formulations across the region.
  • MOUD access remains limited across much of the Gulf versus global standards.
  • Traveler carriage often requires controlled-drug authorization/permit pathways.
  • Regional availability and restrictions are substantial and country-specific.

Saudi Arabia — confirm with local formulary.